Advances in the use of hydroxyurea.

نویسندگان

  • Russell E Ware
  • Banu Aygun
چکیده

Clinical experience with hydroxyurea for patients with sickle cell disease (SCD) has been accumulating for the past 25 years. The bulk of the current evidence suggests that hydroxyurea is well-tolerated, safe, and efficacious for most patients with SCD. Hydroxyurea has proven clinical efficacy for reducing acute vaso-occlusive events including pain episodes and acute chest syndrome. Salutary effects on hematological parameters include increases in fetal hemoglobin (HbF), hemoglobin, and MCV; also significant decreases occur in WBC, ANC, reticulocytes, LDH, and bilirubin. Treatment with hydroxyurea is usually considered for patients with recurrent vaso-occlusive events, but additional indications for treatment may include laboratory markers of disease severity and evidence of chronic organ dysfunction. Ten years ago, the US Food and Drug Administration approved hydroxyurea for adult patients with clinically severe SCD; however, its use in children remains off-label. Despite the large body of evidence regarding its efficacy and safety, hydroxyurea is currently prescribed only sparingly for patients with SCD and therefore has only limited effectiveness for this disorder; barriers to its use need to be identified and overcome.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

بررسی رابطه مصرف هیدروکسی اوره با سنگ های صفراوی در بیمارن بتا تالاسمی ماژور و اینترمدیا

Background and Purpose: Cholelithiasis is a common problem among patients with homozygous major and intermediate β-thalassemia due to chronic hemolysis, ineffective erythropoesis and other factors that causes variety of side effects. Hydroxyurea (HU) decreases hemolysis by increasing HbF production in homozygous β-thalassemia patients. Up to now, there have not been evidences about relationsh...

متن کامل

Cytotoxicity assessment of nanoliposomal Paclitaxel and nanoliposomal Hydroxyurea in MCF-7 cells

Nanotechnology has revolutionized diagnosis and treatment of cancers. Breast cancer is oneof the most prevalent cancers among women. Paclitaxel and hydroxyurea are important drugsin treatment of breast cancer but their use is limited due to a series of significant side effects.On the other hand, nanoliposomes are widely used as nanocarriers for targeted drug delivery.In this study, cytotoxic ef...

متن کامل

Hypothyroidism in β-Thalassemia Intermedia Patients with and without Hydroxyurea

Hydroxyurea (HU) has been successfully used in patients with β-thalassemia intermedia (β-TI). We aimed to evaluate the effect of the long-term use of HU on thyroid function in patients with β-TI. Seventy-five patients with β-TI aged≥11 years and taking HU were randomly selected during 2010 in southern Iran. Thirty-one patients with β-TI without HU were considered as a control group. Serum level...

متن کامل

Side Effects of Hydroxyurea in Patients with Sickle Cell Anemia

Background: Hemoglobin S arises is the result of a point mutation (A-T) in the sixth codon on the -globin gene on chromosome 11 causing sickle cell anemia. The presence of fetal hemoglobin in infancy plays a relatively protective role for vaso-occlusive symptoms that are the major contributor for the morbidity and mortality among patients with sickle cell anemia. hydroxyurea, an s-phase-specif...

متن کامل

Role of XmnIgG Polymorphism in Hydroxyurea Treatment and Fetal Hemoglobin Level at Isfahanian Intermediate β-Thalassemia Patients

Background: &beta-thalassemia is the most common monogenic disorder in human. The (CT) polymorphism at -158 upstream region of the &gammaG-globin gene and pharmacological factors such as hydroxyurea have been reported to influence &gamma-globin gene expression and the severity of clinical symptoms of &beta-thalassemia. Methods: In the present study, 51 &beta-thalassemia intermediate patients w...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Hematology. American Society of Hematology. Education Program

دوره   شماره 

صفحات  -

تاریخ انتشار 2009